PL403800A1 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number
PL403800A1
PL403800A1 PL403800A PL40380002A PL403800A1 PL 403800 A1 PL403800 A1 PL 403800A1 PL 403800 A PL403800 A PL 403800A PL 40380002 A PL40380002 A PL 40380002A PL 403800 A1 PL403800 A1 PL 403800A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
enantiomer
physiologically acceptable
compound
formula
Prior art date
Application number
PL403800A
Other languages
English (en)
Inventor
Jay R. Luly
Yoshisuke Nakasato
Etsuo Ohshima
Geraldine C.B. Harriman
Kenneth G. Carson
Shomir Ghosh
Amy M. Elder
Karen M. Mattia
Original Assignee
Millennium Pharmaceuticals, Inc.
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/989,086 external-priority patent/US20020169155A1/en
Application filed by Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd. filed Critical Millennium Pharmaceuticals, Inc.
Publication of PL403800A1 publication Critical patent/PL403800A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Przedmiotem wynalazku jest kompozycja farmaceutyczna zawierajaca fizjologicznie dopuszczalny nosnik i enancjomer (S) oraz enancjomer (R) zwiazku o wzorze (A) albo jego fizjologicznie dopuszczalnej soli.
PL403800A 2001-11-21 2002-11-13 Kompozycja farmaceutyczna PL403800A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/989,086 US20020169155A1 (en) 1998-09-04 2001-11-21 Chemokine receptor anagonists and methods of use therefor

Publications (1)

Publication Number Publication Date
PL403800A1 true PL403800A1 (pl) 2013-08-19

Family

ID=32713949

Family Applications (2)

Application Number Title Priority Date Filing Date
PL403800A PL403800A1 (pl) 2001-11-21 2002-11-13 Kompozycja farmaceutyczna
PL369599A PL217918B1 (pl) 2001-11-21 2002-11-13 Związki, ich zastosowanie oraz kompozycja je zawierająca

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL369599A PL217918B1 (pl) 2001-11-21 2002-11-13 Związki, ich zastosowanie oraz kompozycja je zawierająca

Country Status (23)

Country Link
EP (3) EP1688418B1 (pl)
JP (5) JP4889920B2 (pl)
KR (3) KR100919346B1 (pl)
CN (3) CN1585772B (pl)
AR (2) AR037394A1 (pl)
AT (1) ATE320431T1 (pl)
AU (1) AU2002352772B2 (pl)
BR (1) BR0213633A (pl)
CA (1) CA2467672C (pl)
CY (1) CY1107243T1 (pl)
DE (2) DE60209937D1 (pl)
DK (1) DK1448566T5 (pl)
ES (2) ES2260497T7 (pl)
IL (3) IL161669A0 (pl)
MY (2) MY142646A (pl)
NO (1) NO328166B1 (pl)
NZ (3) NZ532827A (pl)
PL (2) PL403800A1 (pl)
PT (1) PT1448566E (pl)
SG (2) SG195393A1 (pl)
SI (1) SI1448566T1 (pl)
TW (1) TWI308568B (pl)
ZA (1) ZA200403530B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260497T7 (es) * 2001-11-21 2009-11-05 Millennium Pharmaceuticals, Inc. Antagonistas de receptores de quimioquininas y metodos de uso de los mismos.
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
AU2008333272B2 (en) * 2007-12-03 2012-03-29 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
CN104292142B (zh) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 一种n-芳基杂环丁烷脱芳基方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80449A (pl) *
JPS5250634B2 (pl) 1971-08-23 1977-12-26
JPS61152673A (ja) 1984-12-26 1986-07-11 Kyowa Hakko Kogyo Co Ltd ジベンズ〔ｂ，ｅ〕オキセピン誘導体の製造法
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
JPH0678315B2 (ja) 1988-04-28 1994-10-05 シェリング・コーポレーション 新規なベンゾピリド‐ピペリジン、ピペリジリデンおよびピペラジン化合物、組成物、製造法および利用法
AU2028892A (en) 1991-05-23 1992-12-30 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
EP0524784A1 (en) 1991-07-23 1993-01-27 Schering Corporation Benzopyrido piperidylidene compounds as PAF antagonists
JP3664176B2 (ja) 1992-11-10 2005-06-22 ジェネンテック・インコーポレーテッド Ｃ−ｃ ｃｋｒ−１，ｃ−ｃケモカインレセプター
WO1996031469A1 (en) * 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
JP3048067B2 (ja) * 1995-12-15 2000-06-05 ノボ ノルディスク アクティーゼルスカブ 新規方法
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
DK1049700T3 (da) * 1998-01-21 2006-02-20 Millennium Pharm Inc Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf
EP1109815A1 (en) * 1998-09-04 2001-06-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU6503900A (en) * 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
WO2001029133A1 (en) 1999-10-20 2001-04-26 Kingspan Industrial Insulation Limited Cellular plastic material based on phenolic resin
TW503427B (en) 2000-07-25 2002-09-21 Koninkl Philips Electronics Nv Display tube comprising a mask with vibration damping means
ES2260497T7 (es) * 2001-11-21 2009-11-05 Millennium Pharmaceuticals, Inc. Antagonistas de receptores de quimioquininas y metodos de uso de los mismos.
DE102011084910A1 (de) 2011-10-20 2013-04-25 Wobben Properties Gmbh Verfahren und Vorrichtung zum Einspeisen elektrischen Stroms in ein elektrisches Netz

Also Published As

Publication number Publication date
EP1448566B3 (en) 2009-04-08
EP1448566A2 (en) 2004-08-25
NO328166B1 (no) 2009-12-21
ATE320431T1 (de) 2006-04-15
NZ585746A (en) 2011-12-22
JP2010229136A (ja) 2010-10-14
CA2467672C (en) 2011-06-28
CN1585772B (zh) 2014-06-04
KR20040064283A (ko) 2004-07-16
JP5936669B2 (ja) 2016-06-22
CY1107243T1 (el) 2012-11-21
AU2002352772A1 (en) 2003-06-10
AR090829A2 (es) 2014-12-10
EP2286811B1 (en) 2012-09-05
KR20070118146A (ko) 2007-12-13
DK1448566T3 (da) 2006-07-31
IL161669A0 (en) 2004-09-27
EP1688418A3 (en) 2008-05-14
JP2016138122A (ja) 2016-08-04
JP4889920B2 (ja) 2012-03-07
DK1448566T5 (da) 2009-08-03
PL217918B1 (pl) 2014-09-30
PL369599A1 (pl) 2005-05-02
NZ532827A (en) 2007-09-28
ES2260497T7 (es) 2009-11-05
ES2396186T3 (es) 2013-02-19
TW200303197A (en) 2003-09-01
SI1448566T1 (sl) 2006-08-31
BR0213633A (pt) 2004-08-24
PT1448566E (pt) 2006-08-31
DE60209937D1 (de) 2006-05-11
IL181191A (en) 2012-10-31
NO20042500L (no) 2004-06-15
EP2286811A1 (en) 2011-02-23
EP1448566B1 (en) 2006-03-15
JP2005510565A (ja) 2005-04-21
KR100919346B1 (ko) 2009-09-25
TWI308568B (en) 2009-04-11
CN1585772A (zh) 2005-02-23
MY146601A (en) 2012-08-30
IL161669A (en) 2010-12-30
JP2015083577A (ja) 2015-04-30
MY142646A (en) 2010-12-15
EP1688418A2 (en) 2006-08-09
SG165152A1 (en) 2010-10-28
AU2002352772B2 (en) 2006-10-26
DE60209937T2 (de) 2006-11-30
SG195393A1 (en) 2013-12-30
KR101001092B1 (ko) 2010-12-14
AR037394A1 (es) 2004-11-10
CA2467672A1 (en) 2003-06-05
HK1154504A1 (en) 2012-04-27
KR100952767B1 (ko) 2010-04-14
DE60209937T4 (de) 2009-10-29
HK1063789A1 (en) 2005-01-14
IL181191A0 (en) 2007-07-04
CN104031054A (zh) 2014-09-10
CN1911930A (zh) 2007-02-14
ES2260497T3 (es) 2006-11-01
JP2013209393A (ja) 2013-10-10
NZ596484A (en) 2013-05-31
KR20100010952A (ko) 2010-02-02
JP5878494B2 (ja) 2016-03-08
EP1688418B1 (en) 2017-03-15
ZA200403530B (en) 2005-07-28

Similar Documents

Publication Publication Date Title
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
IS2750B (is) Leiðarafesting
BR9900443A (pt) Esteres de ácido aril acrìlico.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
UA91007C2 (ru) Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
BRPI0415449A (pt) combinações de compostos ativos fungicidas sinergìsticos
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
SG151249A1 (en) 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DK1140918T3 (da) Thrombininhibitorer
AU2003228770A8 (en) Substituted pyrazolopyrimidines
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
SE0101038D0 (sv) Novel compounds
MXPA04005809A (es) Inhibidores de proteinas quinasas.
UY27587A1 (es) Heterociclos terapéuticos
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
DE60201074D1 (en) Pyrazolopyridinderivate
IL165220A0 (en) Novel compounds, their use and preparation
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
MXPA04005151A (es) Compuestos terapeuticos.
ATE325116T1 (de) Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
HRP20080521T3 (en) Orodispersible pharmaceutical composition of an antithrombotic compound